Pricing
  1. JP-listed companies
  3. Financials
  4. Earnings per share

【JP:4597】

Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
Dec 31, 2025-3.8-61.31%
Dec 31, 2024-9.8+47.58%
Dec 31, 2023-6.6-60.52%
Dec 31, 2022-16.8-11.92%
Dec 31, 2021-19-45.85%
Dec 31, 2020-35.2+98.08%
Dec 31, 2019-17.7-31.68%
Dec 31, 2018-26+112.25%
Dec 31, 2017-12.2-33.69%
Dec 31, 2016-18.5-25.65%
Dec 31, 2015-24.8-7.70%
Dec 31, 2014-26.9-19.29%
Dec 31, 2013-33.3+12.98%
Dec 31, 2012-29.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)